It's hard to overstate how well Novo Nordisk (NYSE: NVO) has performed over the past year. The Denmark-based company has even been credited for helping lift the economy of its country. It has routinely delivered excellent financial results and solid clinical progress, things investors interested in drugmakers want to see.

However, following its performance in the past 12 months, some might think it's too late to invest in Novo Nordisk. Is that the case? Let's consider one argument on each side. 

Continue reading

Source Fool.com